Expansion Into New Modalities — During The Pandemic And Beyond
Source: Rentschler Biopharma
Supporting both German mRNA-based COVID-19 vaccine developers BioNTech SE and CureVac N.V., Rentschler Biopharma SE has not only expanded into the promising field of RNA manufacturing. In this interview, Federico Pollano, Senior Vice President, Global Business Development, speaks about the company’s recent expansion into the cell and gene therapy market.
VIEW THE Q&A! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma X
Subscribe to Outsourced Pharma